MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will participate in the upcoming Oppenheimer 36th Annual Healthcare Life Sciences Conference (virtual) and in the TD Cowen 46th Annual Health Care Conference in Boston, MA (U.S.). Managing Director and Group CEO, Dr. Christian Behrenbruch, will take part in a fireside chat with Oppenheimer on Thursday, February 26, 2026 at 4:40 p.m. EST (Friday, Feb 27 at 8:40 a.m. AEDT). K ...

Core Viewpoint - Legence Corp. is set to release its fourth quarter and full-year results for 2025 on March 27, 2026, prior to market opening [1] Group 1: Earnings Release Details - The earnings conference call and webcast will take place on March 27, 2026, at 10:00 am EST to review the results and operations [2] - The call will be available in listen-only mode, with a replay accessible on the company's website until April 27, 2026 [2] Group 2: Company Overview - Legence is a leading provider of engineering, consulting, installation, and maintenance services for mission-critical systems in buildings [3] - The company specializes in designing, fabricating, and installing complex HVAC, process piping, and other mechanical, electrical, and plumbing (MEP) systems, focusing on energy efficiency, reliability, and sustainability [3] - Legence serves over 60% of the Nasdaq-100 Index among its clients, indicating its presence in technically demanding sectors [3]

Convex generates record annual results including $711 million in net incomeAll amounts in U.S. dollars unless otherwise stated TORONTO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Onex Corporation (TSX: ONEX) today announced its financial results for the fourth quarter and year ended December 31, 2025. Onex also released supplemental financial information for Convex Group Limited (“Convex”) for fiscal 2025. “The acquisition of Convex and partnership with AIG is a pivotal moment in Onex’ evolution that meaningfully en ...

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced IEH Corporation (OTCQX: IEHC), a producer of high-performance PCB connectors, has qualified to trade on the OTCQX® Best Market. IEH Corporation upgraded to OTCQX from the OTCID™ Basic Market. IEH Corporation begins trading today on OTCQX under the symbol “IEHC.” U.S. investors can find current financial disclosure and Real-Time ...

Core Viewpoint - AtaiBeckley Inc. is hosting a Virtual Investor Day on March 6, 2026, to present its mission and pipeline of mental health treatments [1][2]. Company Overview - AtaiBeckley Inc. is a clinical-stage biotechnology company focused on developing rapid-acting, durable, and convenient mental health treatments [3]. - The company's pipeline includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder [3]. - BPL-003 is in Phase 3 planning, while VLS-01 and EMP-01 are in Phase 2 clinical development [3]. - The company is also working on a drug discovery program for novel, non-hallucinogenic 5-HT2AR agonists targeting opioid use disorder and TRD [3]. Event Details - The Virtual Investor Day will feature presentations and live Q&A sessions with the executive leadership team and external key opinion leaders [1]. - Investors, analysts, and media members can register for the live webcast, with a replay available afterward on the company's investor website [2].

Core Viewpoint - Bitdeer Technologies Group has announced the pricing of a US$325 million offering of 5.00% Convertible Senior Notes due 2032, increasing from the previously announced US$300 million, with an option for initial purchasers to buy an additional US$50 million [1][2] Group 1: Convertible Notes Offering - The notes will accrue interest at a rate of 5.00% per year, payable semiannually starting September 1, 2026, and maturing on March 1, 2032 [2] - The initial conversion rate is set at 100.7557 Class A ordinary shares per US$1,000 principal amount, equating to an initial conversion price of approximately US$9.93 per share, representing a 25% premium over the offering price [2] - Bitdeer may redeem the notes for cash starting March 6, 2030, under certain conditions, including if the Class A ordinary shares trade at least 130% of the conversion price for 20 trading days [3][4] Group 2: Use of Proceeds - Bitdeer estimates net proceeds from the notes offering to be approximately US$315.1 million, or US$363.7 million if the option for additional notes is fully exercised [7] - The proceeds will be used to cover costs related to capped call transactions, repurchase existing convertible senior notes, and fund datacenter expansion, HPC and AI cloud business expansion, and ASIC mining rig development [7] Group 3: Capped Call Transactions - Bitdeer has entered into capped call transactions to offset potential dilution from the conversion of the notes, with an initial cap price of US$15.88 per Class A ordinary share [8][9] - The capped call transactions are designed to mitigate the impact of any conversion on the market price of the Class A ordinary shares [8] Group 4: Concurrent Registered Direct Offering - Bitdeer has also announced a registered direct offering of 5,503,030 Class A ordinary shares at US$7.94 per share, with settlement scheduled for February 26, 2026 [12] - The net proceeds from this offering will be used in conjunction with the notes offering to repurchase US$135 million of its November 2029 notes for approximately US$138.2 million [12]

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced that Chemtrade Logistics Income Fund (TSX: CHE.UN; OTCQX: CGIFF), a diversified operator and producer of industrial chemicals and services, has qualified to trade on the OTCQX® Best Market. Chemtrade Logistics Income Fund upgraded to OTCQX from the Pink Limited™ Market. Chemtrade Logistics Income Fund begins trading today on OTC ...

Group 1 - Frontline plc will release its preliminary fourth quarter 2025 results on February 27, 2026 [1] - A webcast and conference call will be held at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time) [1] - The results presentation will be available for download from the Investor Relations section of the company's website [1] Group 2 - Participants can attend the conference call via webcast or by registering online for the conference call [2] - A Q&A session will follow the teleconference/webcast, with instructions for submitting questions provided at the beginning [2] - Presentation materials for the teleconference/webcast can be downloaded from the company's website [2]

Company Overview - Eton Pharmaceuticals, Inc is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases [3] - The company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone [3] - Eton has four additional product candidates in late-stage development: Amglidia, ET-700, ET-800, and ZENEO hydrocortisone autoinjector [3] Upcoming Events - Members of Eton's executive leadership team will host one-on-one meetings at the Leerink Partners Global Healthcare Conference on March 11, 2026, in Miami, Florida [1] - Interested parties can schedule a meeting by contacting their Leerink Partners institutional sales representative [2]

Core Viewpoint - Costamare Bulkers Holdings Limited reported its financial results for Q4 2025, showing an adjusted net loss of $1.7 million and highlighting its operational transition following its spin-off from Costamare Inc. [1][2][15] Financial Highlights and Operational Updates - The company had a total debt of $155.6 million and cash of $226.3 million, resulting in a negative net debt position of $70.7 million as of the end of Q4 2025 [4][16]. - Total voyage revenue for the year ended December 31, 2025, was $597.2 million, with Q4 2025 contributing $218.5 million [20][38]. - The average number of vessels in the owned fleet during Q4 2025 was 31.1, with ownership days totaling 2,859 [32][37]. Operating Platform and Strategic Agreements - The company concluded a Strategic Cooperation Agreement with Cargill, transferring a significant portion of its trading portfolio, including chartered-in vessels and cargo transportation commitments [8][15]. - The operating platform is currently focused on Kamsarmax-type vessels, with a fleet that includes 20 third-party owned dry bulk vessels [8][19]. Fleet Renewal and Vessel Transactions - Costamare Bulkers agreed to sell the 2011-built Capesize vessel, Miracle, and the 2008-built Supramax vessel, Clara, generating total capital gains of $7.7 million [17][18]. - The company has also agreed to acquire the 2018-built dry bulk vessel, Koushun, expected to conclude within Q1 - Q2 2026 [10][17]. Market Conditions - The Capesize index has increased due to favorable supply and demand fundamentals, supported by strong exports and improved sentiment [20]. - The Panamax index has benefited from easing US-China tensions and a strong Capesize market, while the Supramax index remains healthy due to strong demand for coal and minor bulks [20].